Invex Therapeutics Ltd. · ASX:IXC
Invex Therapeutics — Corporate Update (September 2021)
16 slides from Invex Therapeutics's corporate update, Sep 27, 2021
Slide 1: Peptron Collaboration & Manufacturing Agreement: Investor Presentation and Conference Call
ASX / Media Release 27 September 2021 Peptron Collaboration & Manufacturing Agreement: Investor Presentation and Conference Call Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (Exenatid
Slide 2: About Invex Therapeutics Ltd
Webcast The presentation and audio can also be accessed via the webcast link: https://services.choruscall.com.au/webcast/invex-h4obwhol.html - ENDS - This release dated 27 September 2021 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Wa
Slide 3: Peptron Collaboration & Manufacturing Agreement
Invex Therapeutics Peptron Collaboration & Manufacturing Agreement Dr Tom Duthy, Executive Director 27 September 2021 ASX Code: IXC
Slide 4: Disclaimer
Disclaimer This presentation (Presentation) is issued by Invex Therapeutics Ltd (ASX:IXC) (the Company or IXC). The information presented in this Presentation may contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on rea
Slide 5: Key Highlights
KEY HIGHLIGHTS A M A J O R M I L E S TON E F O R I N V E X LONG TERM STRATEGIC PARTNER FINANCIAL Establishes a long term strategic Est. $3M in cost savings & strong partner for Invex upon regulatory economics – fixed cost per dose, no clearance(s) for Presendin™ royalties, no commercial milestone pa
Slide 6: About Peptron
About Peptron ▪ Founded in 1997, based in Daejeon, South Korea ▪ Long-Acting Peptide Formulation specialists (SmartDepot™ Technology) ▪ PT320 – long acting Exenatide in Phase II for Parkinson’s Disease ▪ Established 16,000sqM GMP facility for Exenatide formulation in Osong, South Korea in 2018 ▪ Lis
Slide 7: Exclusive Collaboration & Manufacturing Agreement
Exclusive Collaboration & Manufacturing Agreement ▪ Signed 27 September 2021 ▪ Worldwide collaboration, manufacturing and supply agreement for PresendinTM in Idiopathic Intracranial Hypertension (IIH) ▪ A 1x per week, sustained-release (SR) Exenatide microsphere formulation, originally developed by
Slide 8: About Presendin
About PresendinTM ▪ PresendinTM is a sustained release (SR) formulation of Exenatide in a biodegradable poly(lactic-co-glycolic acid) microsphere (PLGA) ▪ PLGA is a well established formulation solution approved by regulators such as the US Food and Drug Administration (FDA) for a variety of human d
Slide 9: Collaboration & Manufacturing Agreement Synergies
Collaboration & Manufacturing Agreement Synergies ▪ Both companies have their own issued patents covering the use of Exenatide to treat: o Neurological conditions: Peptron (e.g. Parkinson’s Disease) Invex – conditions of raised intracranial pressure (ICP) (e.g. IIH) o Orphan Drug Designations: Invex
Slide 10: Patient Benefits of Presendin™
Patient Benefits of Presendin™ PresendinTM once weekly injection offers significant additional patient benefits in IIH ▪ Pharmacokinetic (PK) profile very well suited to IIH requirements as defined by Invex’s Phase II Pressure Study ▪ Fewer injections translates to greater convenience for patients a
Slide 11: Significantly Reduced Activities & Timeline Ahead of Phase III Trial in IIH
Significantly Reduced Activities & Timeline Ahead of Phase III Trial in IIH Reformulation Tolerability ▪ Successfully completed a series of animal pharmacokinetic (PK) ▪ All Presendin™ formulation excipient(s) have been used in already studies in CY2020 with proprietary formulations approved drugs a
Slide 12: Summary
Summary ▪ Peptron have significant formulation and manufacturing expertise with Exenatide and are financially robust ▪ Invex receives the benefit of Peptron’s expertise, existing study data, and supply of Presendin™ at a fixed cost for clinical development and commercial supply ▪ Peptron gains right
Slide 13: Outlook
Outlook ▪ First clinical batches of Presendin™ from Peptron for a Phase III trial anticipated in Q4 CY2021 ▪ Further to the FDA response on the proposed Phase III design received in June 2021, and based on expert feedback, Invex continues to investigate and define its regulatory strategy for IIH and
Slide 14: Company Snapshot
Company Snapshot Company Major Shareholders (as at 4 August 2021) Repurposed, Proven Drug Presendin™ (Exenatide) Directors / Management 16.8% Clinical Stage Entering Phase III Tattarang 11.8% Tisia Nominees Pty Ltd 5.3% Orphan Disease Focus Idiopathic Intracranial Hypertension (IIH) Anthony Grist 4.
Slide 15: Thank you
cue Thank you invex THERAPEUTICS
Slide 16: Contacts
Contacts INVESTORS MEDIA Dr Tom Duthy Margie Livingston Executive Director Ignite Communications +61 402 493 727 +61 438 661 131 tduthy@invextherapeutics.com margie@ignitecommunications.com.au To subscribe to Invex email alerts, please visit www.invextherapeutics.com Follow us on Twitter @InvexThera
Invex Therapeutics — Corporate Update (September 2021) on 6ix